Compass Pathways completed its NDA for COMP360 psilocybin in treatment-resistant depression as Usona, Definium and other psychedelic developers advance.
FDA approved Inovio’s Voceryq with open questions about its delivery device
The FDA has asked Inovio Pharmaceuticals, a company developing DNA-based medicines, to reanalyze its human factors testing of the Cellectra 5PSP, the electroporation device that delivers its newly approved drug Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a pioneering plasmid DNA-based immunotherapy. The agency is also asking it to verify the device’s sharps injury prevention feature.…
What real-world data shows about current cancer care
Only about 5% of adult cancer patients join clinical trials. Experts explain how real-world data fills gaps and what makes it representative and reliable.
The FDA plans its third rare disease policy change in just over a year
On Oct. 14, the FDA announced a plan called the “Rare Disease Framework Initiative,” described in a new white paper, to build a “fit-for-purpose” approach to reviewing drugs and biologics for rare diseases. The FDA says the initiative aims to give developers of rare disease treatments clearer, more consistent guidance on the evidence needed for…
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
On August 25-26, the U.S. Drug Enforcement Administration (DEA) followed up on two Federal Register notices published on July 1 that signaled its intent to temporarily place several synthetic alkaloids associated with Mitragyna speciosa (commonly known as kratom leaf or kratom) in Schedule I of the Controlled Substances Act (CSA). One notice concerned three synthetic…
FDA issues final PDUFA meeting guidance, expands use of written responses
The FDA has finalized new guidelines for meetings between the FDA and sponsors or applicants relating to the development and review of drugs or biological products under the Prescription Drug User Fee Act (PDUFA). The FDA first published the draft guidance on Sept. 22, 2023, when it collected public comment on the guidelines. The final guidelines contain several changes from the draft, including modifying when INTERACT…
AbbVie’s Maviret ends the wait-and-see reality for acute HCV
AbbVie’s Maviret, known as Mavyret (glecaprevir/pibrentasvir) in the U.S., just became the only therapy approved in the EU for both acute and chronic hepatitis C virus (HCV), removing the need to confirm chronicity before treatment. While 2020 clinical guidance already recommended prompt treatment for acute HCV, the drug’s previous chronic-only indication could still lead to additional documentation, reimbursement hurdles or delays.The expanded indication brings the drug’s approved use in line with existing clinical recommendations. “We no longer have…
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
In the U.S. market, generics play a significant role in reducing overall drug spending. The FDA, for instance, estimated that the generics it approved in 2022 alone saved $18.9 billion in their first year on the market. Those savings come out of margins that keep thinning, because generic retail prices are in sustained deflation, as Brookings…
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
Technology transfer enables the movement of documented processes and knowledge from one unit, such as R&D, a pilot plant or an existing manufacturing site, to another, such as an internal site, CMO or CDMO. However, tacit knowledge, expertise that can’t be written down, is often lost in the process. As of 2022, over 86% of…
CNPV: A gamechanger for the pharma industry or simply more chaos?
The FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program was announced in June 2025 to reduce review times for drug and biological products down to 1-2 months compared with 6+ months for conventional drug and biological product applications by implementing a “tumor board” style review process. The program was envisioned to expedite review process of…
FDA commissioner Marty Makary resigns amid pressure from administration
Marty Makary resigned on Tuesday as commissioner of the Food and Drug Administration following rumors that President Donald Trump was planning to fire him. His departure may have been due to a conflict over fruit-flavored vapes. Trump reportedly pressured Makary to authorize the flavored products from Glas Inc., which he opposed because of their appeal…
Protecting innovation in a borderless pharma economy: The reality of globalized pharma innovation
Today’s drug development programs routinely span continents: distributed research teams, multinational clinical trial networks, and complex webs of cross-border licensing, contract manufacturing, and technology transfer. A promising scaffold discovered in Boston may be optimized in London, validated in Chennai, tested in Australia, and manufactured in Ireland before reaching patients worldwide. This creates a core tension:…
Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
The New York Times published a profile of the company Medvi earlier this month, celebrating it as an example of what AI could help a single person do: build a telehealth company its founder projects will be worth $1.8 billion this year despite a closing loophole for telehealth companies selling compounded versions of popular metabolic…
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile portraying MEDVi CEO Matthew Gallagher as a vibe-coded unicorn, the blowback has been swift. Reporting from Futurism, Forrester, Drug Discovery & Development, Business Insider and others has surfaced an FDA warning letter for misbranding compounded GLP-1 drugs, a number of lawsuits and a history…
FDA reverses course, agrees to review Moderna’s mRNA flu vaccine
The FDA has reversed course on Moderna’s mRNA influenza vaccine, agreeing to review a submission it previously refused, the company announced on Wednesday. Moderna said it has received a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 5, 2026. After receiving a Refusal-to-File (RTF) letter from the FDA, Moderna scheduled a Type A…
FDA Drug Unit chief resigns as he is sued
George Tidmarsh, the head of the FDA’s drug division, resigned on Sunday after he was placed on leave Friday, “after the Office of the General Counsel and the Office of the Inspector General were notified of serious concerns about his personal conduct,” Emily Hilliard, an HHS spokeswoman, told ABC News in a statement. Tidmarsh said…
FDA moves against unapproved ingestible fluoride drugs for kids, citing risk-benefit concerns
The FDA has notified manufacturers that it intends to pursue compliance actions against unapproved ingestible fluoride prescription drugs for children. In a Halloween press release, the agency said it was tightening a long-standing regulatory gap for products that have been sold for decades without new-drug approval. In it, Human Services Secretary Robert F. Kennedy Jr.…
Why FDA’s Elsa AI tool was inevitable (and just the beginning)
Every month, thousands of drug-promo packages, ranging from TV spots to banner ads and updated labels, land in the FDA’s queue for 2253 review. The agency tracks “the number of required submissions of promotional communications to FDA on Form 2253 and the total number of submitted materials, as a submission may contain more than one…
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
The FDA is betting big on genAI to transform tedious workflows, setting a June 30 deadline for agency-wide deployment. While details of its plans are scarce at present, using genAI to reduce FDA’s paperwork burden seems inevitable. The broader goal doesn’t qualify as “a high-order AI problem today,” said Vik Bajaj, founder and CEO of…
Trump slams ‘global free ride’ on drug pricing in executive order, orders match to lowest global prices
Branding U.S. drug pricing an “egregious imbalance” in which a nation with “less than five percent of the world’s population … funds around three‑quarters of global pharmaceutical profits,” President Donald Trump on 12 May signed the Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients order. The executive order describes the current dynamic as one in…
FDA’s genAI push could save CDER hundreds of thousands of review hours annually
Determined to slash bureaucratic drag on drug approvals, FDA chief Dr. Martin Makary is ordering every center to plug generative-AI tools into its review pipeline by June 30, an agency-wide gamble that, he says, will turn days of paperwork into minutes of analysis. Multiple independent studies, including from McKinsey, Bain, Capgemini, the Federal Bar Association,…
Trump’s drug‑pricing order could extend small‑molecule runway 4 years
On the surface, President Donald Trump’s latest drug‑pricing order looks like a populist coup. The White House says it will “put American patients first once again,” capping insulin at three cents and promising deeper Medicare savings. Yet nested in the fine print is a directive for HHS to work with Congress to delay Medicare’s power…
What RFK Jr.’s plans to cut 20,000 HHS job could mean for the pharma sector
The pharma industry faces uncertainty as new HHS Secretary Robert F. Kennedy Jr. spearheads a major departmental overhaul aiming for a total reduction of about 20,000 positions (nearly a quarter of the workforce). The cuts build on roughly 10,000 voluntary departures earlier in 2025. A formal plan announced March 27, 2025, initiates Reduction-in-Force (RIF) actions…
Landmark Bio’s mission to prevent cell therapy ‘do-overs’
In the classic Bill Murray comedy Groundhog Day, the main character is stuck reliving the same day—again and again. Biotech startups often face a similar fate when they sprint to first-in-human trials without planning for the realities of large-scale manufacturing. “Many times, researchers rush to get their product tested in humans with processes that are…
4 trends in FDA novel approvals in 2024
An analysis of FDA approvals across these five years shows small molecules remain central to modern therapeutics, even as complex biologics—particularly monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), and next-generation modalities—are on the rise. Steady R&D investment in these advanced approaches reflects growing clinical confidence in targeted therapies that address difficult or rare disease pathways. 1.…






















